SCYNEXIS Proposes 1-for-5 to 1-for-10 Reverse Stock Split to Avoid Nasdaq Delisting
SCYX sits 84% above its 52-week low of $0.565.
Summary
SCYNEXIS is seeking stockholder approval for a reverse stock split to increase its share price and regain compliance with Nasdaq's minimum bid price requirement, crucial for maintaining its listing.
Key Events · Corporate Governance and Compliance · SCYX
-
Reverse Stock Split Proposal
The Board of Directors is recommending a reverse stock split at a ratio ranging from 1-for-5 to 1-for-10, to be determined at the Board's discretion.
-
Nasdaq Delisting Risk
The primary purpose of the reverse stock split is to regain compliance with Nasdaq's $1.00 minimum bid price requirement by June 15, 2026, to avoid delisting.
-
Special Meeting Scheduled
Stockholders will vote on the reverse stock split proposal at a virtual Special Meeting on May 19, 2026.
-
Authorized Shares Reduction
The proposal also includes a proportionate decrease in the number of authorized shares of common stock.
Analysis · SCYX · Life Sciences
The proposed reverse stock split, with a ratio between 1-for-5 and 1-for-10, is a critical measure for SCYNEXIS to avoid delisting from The Nasdaq Capital Market by the June 15, 2026 deadline. While necessary to maintain exchange listing and potentially improve marketability, reverse splits are generally viewed negatively as they often signal underlying issues with a company's stock performance and can lead to further price erosion. Investors should monitor the outcome of the May 19, 2026 Special Meeting and the subsequent impact on the stock's trading price and liquidity.
How filings like this one have moved
In the 30 days to Oct 2, 2026, 36.3% of the 1072 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.57%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SCYX was trading at $1.04 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $49.6M. The 52-week trading range was $0.57 to $1.31. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.